Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Eric Bjerkholt Sells 9,578 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CFO Eric Bjerkholt sold 9,578 shares of the stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $76.01, for a total value of $728,023.78. Following the completion of the transaction, the chief financial officer owned 39,945 shares in the company, valued at approximately $3,036,219.45. The trade was a 19.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Mirum Pharmaceuticals Stock Down 2.2%

Shares of NASDAQ:MIRM opened at $74.31 on Friday. The business’s 50 day simple moving average is $62.19 and its two-hundred day simple moving average is $50.89. The firm has a market cap of $3.73 billion, a P/E ratio of -61.41 and a beta of 0.92. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.97 and a current ratio of 3.13. Mirum Pharmaceuticals, Inc. has a 52-week low of $36.86 and a 52-week high of $78.10.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.19. The firm had revenue of $127.79 million during the quarter, compared to the consensus estimate of $107.91 million. Mirum Pharmaceuticals had a negative return on equity of 24.76% and a negative net margin of 13.65%.The company’s quarterly revenue was up 64.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.52) earnings per share. As a group, research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Stifel Nicolaus set a $89.00 price objective on Mirum Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, August 11th. Wall Street Zen downgraded Mirum Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 25th. JPMorgan Chase & Co. increased their price objective on Mirum Pharmaceuticals from $53.00 to $77.00 and gave the stock an “overweight” rating in a research note on Friday. HC Wainwright increased their price objective on Mirum Pharmaceuticals from $73.00 to $80.00 and gave the stock a “buy” rating in a research note on Thursday, August 7th. Finally, Raymond James Financial reissued a “strong-buy” rating on shares of Mirum Pharmaceuticals in a research note on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. Based on data from MarketBeat, Mirum Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $74.44.

Institutional Trading of Mirum Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the business. Legal & General Group Plc increased its position in shares of Mirum Pharmaceuticals by 0.4% during the second quarter. Legal & General Group Plc now owns 43,010 shares of the company’s stock valued at $2,189,000 after acquiring an additional 176 shares during the last quarter. Teacher Retirement System of Texas increased its position in shares of Mirum Pharmaceuticals by 2.2% during the second quarter. Teacher Retirement System of Texas now owns 9,903 shares of the company’s stock valued at $504,000 after acquiring an additional 215 shares during the last quarter. Palumbo Wealth Management LLC increased its position in shares of Mirum Pharmaceuticals by 4.2% during the second quarter. Palumbo Wealth Management LLC now owns 5,604 shares of the company’s stock valued at $285,000 after acquiring an additional 228 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Mirum Pharmaceuticals by 14.9% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,914 shares of the company’s stock valued at $97,000 after acquiring an additional 248 shares during the last quarter. Finally, Comerica Bank increased its position in shares of Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares during the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.